Novo Holdings, a global life sciences investor, announced its investment in SCHOTT Poonawalla, India's leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals, alongside TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG.

SCHOTT Poonawalla is a joint venture between SCHOTT Pharma AG and the Serum Institute of India and is recognised as India's foremost manufacturer of injectable-focused primary packaging, offering a full range of products including ampoules, vials, cartridges, and prefilled syringes. The company serves over 100 pharmaceutical customers and operates three manufacturing facilities across India with a capacity of over 3 billion units annually.

This investment underscores Novo Holdings' commitment to building long-term partnerships with differentiated healthcare platforms in Asia and further strengthens its presence in the pharmaceutical infrastructure segment. It also marks Novo Holdings' first investment in the Medtech manufacturing space in India and aligns with its strategy to back category-defining life sciences platforms globally. Novo Holdings will continue to support the company's expansion through value creation initiatives and long-term engagement.

"Our investment in SCHOTT Poonawalla reflects our conviction in the strategic importance of high-quality drug delivery systems and the critical role India plays in the global pharmaceutical supply chain," said Amit Kakar, Managing Partner and Head of Asia at Novo Holdings. "We look forward to supporting SCHOTT Poonawalla's next phase of growth alongside TPG and SCHOTT Pharma and help expand its global footprint while ensuring resilient and sustainable supply of essential packaging solutions."

"SCHOTT Poonawalla is a clear market leader in India's injectable packaging space, with a strong reputation for quality, innovation, and reliability," added Navjeewan Khosla, Partner at Novo Holdings Asia. "We see significant opportunity to add value by leveraging Novo Holdings' life sciences network, experience in Medtech, and strong global partnerships across the biopharma industry."